PubMed:26810187 JSON TXT

Annnotations TAB JSON ListView MergeView

DisGeNET5_gene_disease

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"26810187-0#0#6#gene5111","span":{"begin":108,"end":114},"obj":"gene5111"},{"id":"26810187-0#70#75#gene2064","span":{"begin":573,"end":578},"obj":"gene2064"},{"id":"26810187-0#93#106#diseaseC0006142","span":{"begin":596,"end":609},"obj":"diseaseC0006142"},{"id":"26810187-0#93#106#diseaseC0678222","span":{"begin":596,"end":609},"obj":"diseaseC0678222"},{"id":"26810187-0#93#106#diseaseC0006142","span":{"begin":596,"end":609},"obj":"diseaseC0006142"},{"id":"26810187-0#93#106#diseaseC0678222","span":{"begin":596,"end":609},"obj":"diseaseC0678222"}],"relations":[{"id":"0#6#gene511193#106#diseaseC0006142","pred":"associated_with","subj":"26810187-0#0#6#gene5111","obj":"26810187-0#93#106#diseaseC0006142"},{"id":"0#6#gene511193#106#diseaseC0678222","pred":"associated_with","subj":"26810187-0#0#6#gene5111","obj":"26810187-0#93#106#diseaseC0678222"},{"id":"0#6#gene511193#106#diseaseC0006142","pred":"associated_with","subj":"26810187-0#0#6#gene5111","obj":"26810187-0#93#106#diseaseC0006142"},{"id":"0#6#gene511193#106#diseaseC0678222","pred":"associated_with","subj":"26810187-0#0#6#gene5111","obj":"26810187-0#93#106#diseaseC0678222"},{"id":"70#75#gene206493#106#diseaseC0006142","pred":"associated_with","subj":"26810187-0#70#75#gene2064","obj":"26810187-0#93#106#diseaseC0006142"},{"id":"70#75#gene206493#106#diseaseC0678222","pred":"associated_with","subj":"26810187-0#70#75#gene2064","obj":"26810187-0#93#106#diseaseC0678222"},{"id":"70#75#gene206493#106#diseaseC0006142","pred":"associated_with","subj":"26810187-0#70#75#gene2064","obj":"26810187-0#93#106#diseaseC0006142"},{"id":"70#75#gene206493#106#diseaseC0678222","pred":"associated_with","subj":"26810187-0#70#75#gene2064","obj":"26810187-0#93#106#diseaseC0678222"}],"text":"Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.\nCyclin E is a well-characterized cell cycle regulator and an amplified oncogene in breast cancer. Over-expression of cyclin E has generally been associated with poor survival. Recent studies have shown an interaction between HER-2 (ERBB2) and cyclin E, but the exact mechanism is unknown. Interestingly, cyclin E over-expression has been associated with trastuzumab resistance. We studied cyclin E over-expression, CCNE1 amplification, and relapse-free survival in HER-2-positive primary breast cancers treated with and without trastuzumab therapy. Formalin-fixed paraffin-embedded tissue samples from 202 HER-2-positive breast carcinomas were studied. Expression levels of cyclin E and proliferation marker Ki-67 were determined using immunohistochemistry. Chromogenic in situ hybridization (CISH) with a gene-specific bacterial artificial chromosome (BAC) probe was used to analyze presence of CCNE1 amplification. Majority of HER-2-positive breast carcinomas exhibited nuclear staining for cyclin E protein. Cyclin E was highly expressed (≥50 % cells) in 37 % of cases. Incidence of CCNE1 amplification (≥6 gene copies/cell or clusters) was 8 %. Cyclin E amplification and over-expression were strongly associated with each other, grade, hormone receptors, and Ki-67. Neither high cyclin E expression nor CCNE1 amplification was associated with relapse-free survival (RFS) irrespective of short-term (9-week regimen) adjuvant trastuzumab therapy. These results confirm cyclin E and HER-2 gene co-amplification in a fraction of HER-2-positive breast cancers. Cyclin E is frequently over-expressed but appears to have limited value as a prognostic or predictive factor in HER-2-positive breast cancer regardless of trastuzumab therapy."}

DisGeNet-2017-sample

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T1842","span":{"begin":108,"end":114},"obj":"gene:5111"},{"id":"T1843","span":{"begin":596,"end":609},"obj":"disease:C0006142"},{"id":"T1844","span":{"begin":573,"end":578},"obj":"gene:2064"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T1842","obj":"T1843"},{"id":"R2","pred":"associated_with","subj":"T1842","obj":"T1843"},{"id":"R3","pred":"associated_with","subj":"T1844","obj":"T1843"},{"id":"R4","pred":"associated_with","subj":"T1844","obj":"T1843"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.\nCyclin E is a well-characterized cell cycle regulator and an amplified oncogene in breast cancer. Over-expression of cyclin E has generally been associated with poor survival. Recent studies have shown an interaction between HER-2 (ERBB2) and cyclin E, but the exact mechanism is unknown. Interestingly, cyclin E over-expression has been associated with trastuzumab resistance. We studied cyclin E over-expression, CCNE1 amplification, and relapse-free survival in HER-2-positive primary breast cancers treated with and without trastuzumab therapy. Formalin-fixed paraffin-embedded tissue samples from 202 HER-2-positive breast carcinomas were studied. Expression levels of cyclin E and proliferation marker Ki-67 were determined using immunohistochemistry. Chromogenic in situ hybridization (CISH) with a gene-specific bacterial artificial chromosome (BAC) probe was used to analyze presence of CCNE1 amplification. Majority of HER-2-positive breast carcinomas exhibited nuclear staining for cyclin E protein. Cyclin E was highly expressed (≥50 % cells) in 37 % of cases. Incidence of CCNE1 amplification (≥6 gene copies/cell or clusters) was 8 %. Cyclin E amplification and over-expression were strongly associated with each other, grade, hormone receptors, and Ki-67. Neither high cyclin E expression nor CCNE1 amplification was associated with relapse-free survival (RFS) irrespective of short-term (9-week regimen) adjuvant trastuzumab therapy. These results confirm cyclin E and HER-2 gene co-amplification in a fraction of HER-2-positive breast cancers. Cyclin E is frequently over-expressed but appears to have limited value as a prognostic or predictive factor in HER-2-positive breast cancer regardless of trastuzumab therapy."}

sentences

UBERON-AE

{"project":"UBERON-AE","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":93,"end":99},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":191,"end":197},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":596,"end":602},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":729,"end":735},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":1052,"end":1058},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":1653,"end":1659},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":1796,"end":1802},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":690,"end":696},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"}],"text":"Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.\nCyclin E is a well-characterized cell cycle regulator and an amplified oncogene in breast cancer. Over-expression of cyclin E has generally been associated with poor survival. Recent studies have shown an interaction between HER-2 (ERBB2) and cyclin E, but the exact mechanism is unknown. Interestingly, cyclin E over-expression has been associated with trastuzumab resistance. We studied cyclin E over-expression, CCNE1 amplification, and relapse-free survival in HER-2-positive primary breast cancers treated with and without trastuzumab therapy. Formalin-fixed paraffin-embedded tissue samples from 202 HER-2-positive breast carcinomas were studied. Expression levels of cyclin E and proliferation marker Ki-67 were determined using immunohistochemistry. Chromogenic in situ hybridization (CISH) with a gene-specific bacterial artificial chromosome (BAC) probe was used to analyze presence of CCNE1 amplification. Majority of HER-2-positive breast carcinomas exhibited nuclear staining for cyclin E protein. Cyclin E was highly expressed (≥50 % cells) in 37 % of cases. Incidence of CCNE1 amplification (≥6 gene copies/cell or clusters) was 8 %. Cyclin E amplification and over-expression were strongly associated with each other, grade, hormone receptors, and Ki-67. Neither high cyclin E expression nor CCNE1 amplification was associated with relapse-free survival (RFS) irrespective of short-term (9-week regimen) adjuvant trastuzumab therapy. These results confirm cyclin E and HER-2 gene co-amplification in a fraction of HER-2-positive breast cancers. Cyclin E is frequently over-expressed but appears to have limited value as a prognostic or predictive factor in HER-2-positive breast cancer regardless of trastuzumab therapy."}

performance-test

{"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":690,"end":696},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":93,"end":99},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":191,"end":197},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":596,"end":602},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":729,"end":735},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":1052,"end":1058},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":1653,"end":1659},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":1796,"end":1802},"obj":"http://purl.obolibrary.org/obo/UBERON_0000310"}],"text":"Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.\nCyclin E is a well-characterized cell cycle regulator and an amplified oncogene in breast cancer. Over-expression of cyclin E has generally been associated with poor survival. Recent studies have shown an interaction between HER-2 (ERBB2) and cyclin E, but the exact mechanism is unknown. Interestingly, cyclin E over-expression has been associated with trastuzumab resistance. We studied cyclin E over-expression, CCNE1 amplification, and relapse-free survival in HER-2-positive primary breast cancers treated with and without trastuzumab therapy. Formalin-fixed paraffin-embedded tissue samples from 202 HER-2-positive breast carcinomas were studied. Expression levels of cyclin E and proliferation marker Ki-67 were determined using immunohistochemistry. Chromogenic in situ hybridization (CISH) with a gene-specific bacterial artificial chromosome (BAC) probe was used to analyze presence of CCNE1 amplification. Majority of HER-2-positive breast carcinomas exhibited nuclear staining for cyclin E protein. Cyclin E was highly expressed (≥50 % cells) in 37 % of cases. Incidence of CCNE1 amplification (≥6 gene copies/cell or clusters) was 8 %. Cyclin E amplification and over-expression were strongly associated with each other, grade, hormone receptors, and Ki-67. Neither high cyclin E expression nor CCNE1 amplification was associated with relapse-free survival (RFS) irrespective of short-term (9-week regimen) adjuvant trastuzumab therapy. These results confirm cyclin E and HER-2 gene co-amplification in a fraction of HER-2-positive breast cancers. Cyclin E is frequently over-expressed but appears to have limited value as a prognostic or predictive factor in HER-2-positive breast cancer regardless of trastuzumab therapy."}